Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ke-Min-Qi-Dan is a traditional Chinese medicine (TCM) formulation administered as a nasal spray. It is being investigated for its effects on allergic rhinitis with qi deficiency and blood stasis syndrome, conditions described within the TCM framework. The mechanism of action is not fully elucidated in biomedical terms but may involve modulation of immune and inflammatory pathways, as suggested by studies examining its impact on miR21, ECP (eosinophil cationic protein), and IL-4 networks. Clinical trials are ongoing to explore its efficacy and mechanism in regulating the balance of tendon and bone metabolism in patients with these TCM syndromes[2][3]. The product appears to be developed within China, specifically at institutions such as the Hospital of Chengdu University of Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ke-Min-Qi-Dan.